Rafael Holdings, Inc. RFL Infusion Technology — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rafael Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Rafael Holdings, Inc.’s 10-Q, filed June 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rafael Holdings, Inc.'s infusion technology — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rafael Holdings, Inc.'s infusion technology — research and development expense?
- Rafael Holdings, Inc. (RFL) reported infusion technology — research and development expense of $1K in Q1 2026.
- What does infusion technology — research and development expense mean?
- Captures the costs incurred by the Infusion Technology segment to discover, develop, and improve products or technologies. This reflects the company's commitment to innovation and future growth potential within the infusion space. High levels of investment in this area are typical for clinical-stage or technology-focused segments aiming to build a competitive pipeline.